Potential smoothened inhibitor from traditional Chinese medicine against the disease of diabetes, obesity, and cancer

BioMed Research International

Volumn 2014, Issue , 2014, Pages

  Chen, Kuan Chung ^a   Sun, Mao Feng ^a,b   Chen, Hsin Yi ^c   Lee, Cheng Chun ^d   Chen, Calvin Yu Chian ^a,b,c,d  

^a CHINA MEDICAL UNIVERSITY   (Taiwan)

^b CHINA MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^c ASIA UNIVERSITY   (Taiwan)

^d CHINA MEDICAL UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

2,2' [BENZENE 1,4 DIYLBIS(METHANEDIYLOXYBENZENE 4,1 DIYL)]BIS(OXOACETIC ACID); LABIATIC ACID; PRECATORINE; PROTEIN INHIBITOR; SMOOTHENED PROTEIN; TALADEGIB; UNCLASSIFIED DRUG; G PROTEIN COUPLED RECEPTOR; PHTHALAZINE DERIVATIVE; SMO PROTEIN, HUMAN;

ABRUS; ARDISIA; ARDISIA JAPONICA; ARTICLE; BINDING AFFINITY; CHINESE MEDICINE; CONTROLLED STUDY; DIABETES MELLITUS; DRUG BINDING; DRUG BINDING SITE; DRUG CONFORMATION; DRUG PROTEIN BINDING; DRUG STABILITY; HYDROGEN BOND; LIGAND BINDING; MOLECULAR DOCKING; MOLECULAR DYNAMICS; NEOPLASM; NONHUMAN; OBESITY; PROTEIN FOLDING; ROSEMARY; SURFACE AREA; ANTAGONISTS AND INHIBITORS; BINDING SITE; CHEMISTRY; DIABETES MELLITUS, TYPE 2; HUMAN; METABOLISM; NEOPLASMS; PATHOLOGY; PROTEIN CONFORMATION; TAIWAN; X RAY CRYSTALLOGRAPHY;

BINDING SITES; CRYSTALLOGRAPHY, X-RAY; DIABETES MELLITUS, TYPE 2; HUMANS; MEDICINE, CHINESE TRADITIONAL; MOLECULAR DOCKING SIMULATION; MOLECULAR DYNAMICS SIMULATION; NEOPLASMS; OBESITY; PHTHALAZINES; PROTEIN CONFORMATION; RECEPTORS, G-PROTEIN-COUPLED; TAIWAN;

EID: 84929055234     PISSN: 23146133     EISSN: 23146141     Source Type: Journal    
DOI: 10.1155/2014/873010     Document Type: Article

References (46)

1. K. Jauch-Chara and K. M. Oltmanns, "Obesity-a neuropsychological disease? Systematic review and neuropsychological model, " Progress in Neurobiology, vol. 114, pp. 84-101, 2014.
2. A. J. Guri, R. Hontecillas, and J. Bassaganya-Riera, "Peroxisome proliferator-activated receptors: bridging metabolic syndrome with molecular nutrition, " Clinical Nutrition, vol. 25, no. 6, pp. 871-885, 2006.
3. R. Teperino, S. Amann, M. Bayer et al. , "Hedgehog partial agonism drives warburg-like metabolism in muscle and brown fat, " Cell, vol. 151, no. 2, pp. 414-426, 2012.
4. Y. Jiang, X. Li, W. Yang et al. , "PKM2 regulates chromosome segregation and mitosis progression of tumor cells, " Molecular Cell, vol. 53, no. 1, pp. 75-87, 2014.
5. Y.-M. Chang, B. K. Velmurugan, W.-W. Kuo et al. , "Inhibitory effect of alpinate Oxyphyllae fructus extracts on Ang IIinduced cardiac pathological remodeling-related pathways in H9c2 cardiomyoblast cells, " BioMedicine, vol. 3, no. 4, pp. 148-152, 2013.
6. Y. M. Leung, K. L. Wong, S. W. Chen et al. , "Down-regulation of voltage-gated Ca2+ channels in Ca2+ store-depleted rat insulinoma RINm5F cells, " BioMedicine, vol. 3, no. 3, pp. 130-139, 2013.
7. M. A. Leissring, E. Malito, S. Hedouin et al. , "Designed inhibitors of insulin-degrading enzyme regulate the catabolism and activity of insulin, " PLoS ONE, vol. 5, no. 5, Article ID e10504, 2010.
8. C.-L. Jao, S.-L. Huang, and K.-C. Hsu, "Angiotensin Iconverting enzyme inhibitory peptides: inhibition mode, bioavailability, and antihypertensive effects, " BioMedicine, vol. 2, no. 4, pp. 130-136, 2012.
9. A. P. McMahon, P. W. Ingham, and C. J. Tabin, "Developmental roles and clinical significance of Hedgehog signaling, " Current Topics in Developmental Biology, vol. 53, pp. 1-114, 2003.
10. S. J. Scales and F. J. de Sauvage, "Mechanisms of Hedgehog pathway activation in cancer and implications for therapy, " Trends in Pharmacological Sciences, vol. 30, no. 6, pp. 303-312, 2009.
11. A. Sekulic, A. R. Mangold, D. W. Northfelt, and P. M. Lorusso, "Advanced basal cell carcinoma of the skin: targeting the Hedgehog pathway, " Current Opinion in Oncology, vol. 25, no. 3, pp. 218-223, 2013.
12. R. McMillan and W. Matsui, "Molecular pathways: the hedgehog signaling pathway in cancer, " Clinical Cancer Research, vol. 18, no. 18, pp. 4883-4888, 2012.
13. V. Chenna, C. Hu, and S. R. Khan, "Synthesis and cytotoxicity studies of Hedgehog enzyme inhibitors SANT-1 and GANT-61 as anticancer agents, " Journal of Environmental Science and Health A: Toxic/Hazardous Substances and Environmental Engineering, vol. 49, no. 6, pp. 641-647, 2014.
14. D. Amakye, Z. Jagani, and M. Dorsch, "Unraveling the therapeutic potential of the Hedgehog pathway in cancer, " Nature Medicine, vol. 19, no. 11, pp. 1410-1422, 2013.
15. D. D. Von Hoff, P. M. LoRusso, C. M. Rudin et al. , "Inhibition of the hedgehog pathway in advanced basal-cell carcinoma, " The New England Journal ofMedicine, vol. 361, no. 12, pp. 1164-1172, 2009.
16. A. E. Proctor, L. A. Thompson, and C. L. OBryant, "Vismodegib: an inhibitor of the hedgehog signaling pathway in the treatment of basal cell carcinoma, " The Annals of Pharmacotherapy, vol. 48, no. 1, pp. 99-106, 2014.
17. M. Xin, L. Zhang, F. Tang et al. , "Design, synthesis, and evaluation of pyrrolo[2, 1-f][1, 2, 4]triazine derivatives as novel hedgehog signaling pathway inhibitors, " Bioorganic&Medicinal Chemistry, vol. 22, no. 4, pp. 1429-1440, 2014.
18. R. Kunstfeld, "Smoothened inhibitors in the treatment of advanced basal cell carcinomas, " Current Opinion in Oncology, vol. 26, no. 2, pp. 184-195, 2014.
19. C. Y. Chen, "A novel integrated framework and improved methodology of computer-aided drug design, " Current Topics in Medicinal Chemistry, vol. 13, no. 9, pp. 965-988, 2013.
20. C. Y. Chen and C. Y. C. Chen, "Insights into designing the dual-targeted HER2/HSP90 inhibitors, " Journal of Molecular Graphics and Modelling, vol. 29, no. 1, pp. 21-31, 2010.
21. S. C. Yang, S. S. Chang, H. Y. Chen, and C. Y. C. Chen, "Identification of potent EGFR inhibitors from TCM Database@Taiwan, " PLoS Computational Biology, vol. 7, no. 10, Article ID e1002189, 2011.
22. Y. A. Tsou, K. C. Chen, H. C. Lin, S. S. Chang, and C. Y. C. Chen, "Uroporphyrinogen decarboxylase as a potential target for specific components of Traditional Chinese Medicine: a virtual screening and molecular dynamics study, " PLoS ONE, vol. 7, no. 11, Article ID e50087, 2012.
23. Y. A. Tsou, K. C. Chen, S. S. Chang, Y. R. Wen, and C. Y. Chen, "A possible strategy against head and neck cancer: in silico investigation of three-in-one inhibitors, " Journal of Biomolecular Structure and Dynamics, vol. 31, no. 12, pp. 1358-1369, 2013.
24. K. C. Chen, S. S. Chang, F. J. Tsai, and C. Y. Chen, "Han ethnicity-specific type 2 diabetic treatment from Traditional Chinese Medicine" Journal of Biomolecular Structure and Dynamics, vol. 31, no. 11, pp. 1219-1235, 2013.
25. K. C. Chen, M. F. Sun, S. C. Yang et al. , "Investigationintopotent inflammation inhibitors from Traditional Chinese Medicine, " Chemical Biology and Drug Design, vol. 78, no. 4, pp. 679-688, 2011.
26. S. S. Chang, H. J. Huang, and C. Y. Chen, "Two birds with one stone? Possible dual-targeting H1N1 inhibitors fromTraditional Chinese Medicine, " PLoS Computational Biology, vol. 7, no. 12, Article ID e1002315, 2011.
27. H. J. Huang, K. J. Lee, H. W. Yu, H. Chen, F. Tsai, and C. Y. Chen, "Anovel strategy for designing the selective PPAR agonist by the "sum of activity" model, " Journal of Biomolecular Structure and Dynamics, vol. 28, no. 2, pp. 187-200, 2010.
28. K. C. Chen, S. S. Chang, H. J. Huang, T. Lin, Y. Wu, and C. Y. Chen, "Three-in-one agonists for PPAR-α, PPAR-, and PPAR- from Traditional Chinese Medicine, " Journal of Biomolecular Structure and Dynamics, vol. 30, no. 6, pp. 662-683, 2012.
29. K.-C. Chen and C. Y. C. Chen, "Stroke prevention by Traditional Chinese Medicine? A genetic algorithm, support vector machine and molecular dynamics approach, " SoftMatter, vol. 7, no. 8, pp. 4001-4008, 2011.
30. K. C. Chen, K. W. Chang, H. Y. Chen, and C. Y. C. Chen, "Traditional Chinese Medicine, a solution for reducing dual stroke risk factors at once" Molecular BioSystems, vol. 7, no. 9, pp. 2711-2719, 2011.
31. T. T. Chang, K. C. Chen, K. W. Chang et al. , "In silico pharmacology suggests ginger extractsmay reduce stroke risks, " Molecular BioSystems, vol. 7, no. 9, pp. 2702-2710, 2011.
32. W. Ieongtou, S. S. Chang, D. Wu et al. , "Molecular level activation insights from a NR2A/NR2B agonist, " Journal of Biomolecular Structure and Dynamics, vol. 32, no. 5, pp. 683-693, 2014.
33. H. J. Huang, Y. R. Jian, and C. Y. Chen, "Traditional Chinese Medicine application in HIV: an in silico study, " Journal of Biomolecular Structure and Dynamics, vol. 32, no. 1, pp. 1-12, 2014.
34. W. I. Tou, S. S. Chang, C. C. Lee, and C. Y. Chen, "Drug design for neuropathic pain regulation from Traditional Chinese Medicine, " Scientific Reports, vol. 3, p. 844, 2013.
35. K. C. Chen, Y. R. Jian, M. F. Sun, T. T. Chang, C. C. Lee, and C. Y. Chen, "Investigation of silent information regulator 1 (Sirt1) agonists from Traditional Chinese Medicine, " Journal of Biomolecular Structure and Dynamics, vol. 31, no. 11, pp. 1207-1218, 2013.
36. C. Y. C. Chen, "TCM Database@Taiwan: the world's largest Traditional Chinese Medicine database for drug screening in silico, " PLoS ONE, vol. 6, no. 1, Article ID e15939, 2011.
37. W. I. Tou and C. Y. Chen, "May disordered protein cause serious drug side effect" Drug Discovery Today, vol. 19, no. 4, pp. 367-372, 2014.
38. C. Y. C. Chen and W. I. Tou, "How to design a drug for the disordered proteins" Drug Discovery Today, vol. 18, no. 19-20, pp. 910-915, 2013.
39. C. Wang, H. Wu, V. Katritch et al. , "Structure of the human smoothened receptor bound to an antitumour agent, " Nature, vol. 497, no. 7449, pp. 338-343, 2013.
40. B. Xue, R. L. Dunbrack, R. W. Williams, A. K. Dunker, and V. N. Uversky, "PONDR-FIT: a meta-predictor of intrinsically disordered amino acids, " Biochimica et Biophysica Acta-Proteins and Proteomics, vol. 1804, no. 4, pp. 996-1010, 2010.
41. B. R. Brooks, R. E. Bruccoleri, B. D. Olafson, D. J. States, S. Swaminathan, and M. Karplus, "CHARMM: a program for macromolecular energy minimization and dynamics calculations, " Journal of ComputationalChemistry, vol. 4, no. 2, pp. 187-217, 1983.
42. C. A. Lipinski, F. Lombardo, B. W. Dominy, and P. J. Feeney, "Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings, " Advanced Drug Delivery Reviews, vol. 46, no. 1-3, pp. 3-26, 2001.
43. C. M. Venkatachalam, X. Jiang, T. Oldfield, and M. Waldman, "LigandFit: a novel method for the shape-directed rapid docking of ligands to protein active sites, " Journal of Molecular Graphics and Modelling, vol. 21, no. 4, pp. 289-307, 2003.
44. B. Hess, C. Kutzner, D. van der Spoel, and E. Lindahl, "GRGMACS 4: algorithms for highly efficient, load-balanced, and scalable molecular simulation, " Journal of ChemicalTheory and Computation, vol. 4, no. 3, pp. 435-447, 2008.
45. V. Zoete, M. A. Cuendet, A. Grosdidier, and O. Michielin, "SwissParam: a fast force field generation tool for small organic molecules, " Journal of Computational Chemistry, vol. 32, no. 11, pp. 2359-2368, 2011.
46. R. Fletcher, Optimization, Academic Press, New York, NY, USA, 1969.